EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis

Silvio Danese iD, Rupert W Leong iD, Bruce E Sands, Tony Ma, Colleen Marano, Laurent Peyrin-Biroulet iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70264 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Silvio Danese und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Ustekinumab, Colitis, Ulcerative, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Achievement of disease clearance (simultaneous symptomatic remission and histo‐endoscopic mucosal improvement [HEMI]) following induction therapy may lead to better long‐term outcomes in ulcerative colitis (UC).

Aim

To evaluate disease clearance in the phase 3 UNIFI program and its association with long‐term outcomes.

Methods

UNIFI comprised randomised, placebo‐controlled induction and maintenance studies and a long‐term extension, which evaluated intravenous ustekinumab induction (130 mg or ~6 mg/kg) and subcutaneous ustekinumab maintenance therapy (90 mg every 8 or 12 weeks) through 4 years in patients with UC.

Results

Disease clearance was achieved by 5.9%, 15.2% and 15.1% of patients 8 weeks after placebo or ustekinumab 130 mg or ~6 mg/kg induction, respectively. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who did or did not achieve disease clearance 8 weeks after induction, 63.6% and 35.2% (nominal p < 0.001), respectively, achieved clinical remission (Mayo score ≤ 2, no individual subscore > 1) at Week 44. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who achieved disease clearance, symptomatic remission without HEMI, or neither symptomatic remission nor HEMI 8 weeks after induction, 73.4%, 53.5% (nominal p = 0.002) and 45.1% (nominal p < 0.001), respectively, achieved symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and 58.2%, 46.5% (nominal p = 0.09) and 42.7% (nominal p = 0.05), respectively, achieved Inflammatory Bowel Disease Questionnaire remission (score ≥ 170) at Week 200.

Conclusions

Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long‐term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. Trial Registration NCT02407236

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabColitis, UlcerativeAntibodies, Monoclonal, HumanizedHumansFemaleMaleAdultTreatment OutcomeMiddle AgedRemission InductionDouble-Blind MethodMaintenance ChemotherapyYoung AdultTime Factors

Stichwörter der Autor:innen

disease clearanceulcerative colitisustekinumab

Substanzen

UstekinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Department of Gastroenterology, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
  • Department of Gastroenterology, Macquarie University Hospital, Sydney, New South Wales, Australia.
  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Biostatistics, Johnson & Johnson, Horsham, Pennsylvania, USA.
  • Immunology, Johnson & Johnson, Spring House, Pennsylvania, USA.

ORCID-Profile: Silvio Danese, Rupert W Leong, Laurent Peyrin-Biroulet

Förderung

  • Johnson and Johnson

Zitieren

APA

Danese, S., Leong, R. W., Sands, B. E., Ma, T., Marano, C., & Peyrin-Biroulet, L. (2025). Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70264

Vancouver

Danese S, Leong RW, Sands BE, Ma T, Marano C, Peyrin-Biroulet L. Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70264

BibTeX
@article{Danese2025,
  author = {Danese, Silvio and Leong, Rupert W and Sands, Bruce E and Ma, Tony and Marano, Colleen and Peyrin-Biroulet, Laurent},
  title = {Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70264}
}
Kostenlos starten →